HIMS Q2 Results Top Estimates; Shares Gain 13.6% Pre-Market

Shares of California-based telehealth firm Hims & Hers Health (HIMS) gained 13.6% in early trade on Thursday after the company reported better-than-expected financial results for the second quarter of 2021. Hims & Hers enables consumers to access medical treatment for dermatology, sexual health, mental health and primary care, among others, by connecting them to licensed healthcare professionals.

Don't Miss our Black Friday Offers:

Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

The company reported a loss of $0.05 per share, narrower than the Street’s loss estimate of $0.10 per share but wider than the year-ago loss of $0.03 per share. Quarterly revenues surged 69% year-over-year to $60.7 million, surpassing analysts’ expectations of $56.49 million. The rise was driven by growth across all business segments.

For the third quarter, Hims & Hers expects revenues to be in the range of $69 million to $71 million. Furthermore, it projects revenues to lie between $251 million and $255 million in 2021. (See Hims & Hers stock chart on TipRanks)

The CEO of Hims & Hers Health, Andrew Dudum, said, “We are building Hims & Hers into the new front door to healthcare. A new front door that will span dozens of medical specialties, welcoming customers of all demographics into a unified consumer platform that looks and feels and talks to them in a way that gives them the confidence they’re in the right hands.”

Last month, BofA Securities analyst Michael Cherny initiated coverage on the stock with a Hold rating and a price target of $12 (33.9% upside potential). The analyst said, “Hims has strong growth potential, but the company operates in a highly competitive market with multiple well-established incumbents, painting the risk-reward potential as balanced.”

Overall, the stock has a Moderate Buy consensus based on 2 Buys and 2 Holds. The average Hims & Hers Health price target of $13.5 implies 56.8% upside potential. Shares of the company have lost 66.3% over the past year.